Premium
A case of macroprolactinoma and elevated insulin‐like growth factor‐I in a young boy
Author(s) -
Eyal Ori,
Naffaa Le,
Elder Deborah A
Publication year - 2005
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.2005.tb01869.x
Subject(s) - prolactinoma , cabergoline , endocrinology , medicine , prolactin , acromegaly , basal (medicine) , bromocriptine , dopamine agonist , dopamine , insulin like growth factor , pituitary tumors , hormone , growth factor , insulin , growth hormone , receptor , dopaminergic
We report a case of a 10‐y‐old boy who presented with persistent headache and was found to have a giant prolactinoma. Laboratory evaluation revealed markedly elevated prolactin (PRL) level, thyroid‐stimulating hormone (TSH) deficiency, and elevated insulin‐like growth factor‐I (IGF‐I). He had normal random growth hormone (GH) but non‐suppressible GH during oral glucose tolerance test (OGTT). Cabergoline treatment was initiated and was well tolerated. Therapy successfully reduced PRL levels, normalized IGF‐I levels, and reduced tumor size. Conclusion: Our patient presented with a GH‐PRL‐secreting tumor. Dopamine agonists are recommended as the treatment of choice for prolactinomas. However, there should be careful attention to GH status when treating GH‐PRL‐secreting tumor with dopamine agonists alone. IGF‐I levels should be followed in all patients with prolactinoma, even in those with normal basal GH concentrations, because of the possibility of GH co‐secretion.